[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 19, 1995

Screening for Prostate Cancer

Author Affiliations

University of Michigan Medical Center Ann Arbor

JAMA. 1995;273(15):1175. doi:10.1001/jama.1995.03520390031021

To the Editor.  —We commend Dr Krahn and colleagues1 for their outstanding decision analysis on screening for prostate cancer. They collected and effectively used available literature for a sophisticated Markov model analysis. Despite the use of an artificial one-time screening scenario, their evaluation avoids the bias evident in the accompanying Editorial.2The authors provide recommendations regarding PSA and transrectal ultrasound (TRUS), but fail to address the role of DRE. Available literature provides no evidence supporting DRE as a screening test for prostate cancer or colorectal cancer. While the authors appear to include DRE in their conclusion "screening for prostate cancer cannot be justified as a rational health policy,"1 they leave DRE out of their recommendation that "asymptomatic men not be screened with PSA or TRUS."1 Their data support not screening with DRE.The article and Editorial2 illustrate a difference between generalists' and specialists' approach to prostate

First Page Preview View Large
First page PDF preview
First page PDF preview